People_
Associate Professor Harriet Gee
MBBS, DPhil, FRANZCR
Clinical Senior Lecturer
Medicine, Westmead Clinical School
Medicine, Westmead Clinical School
Phone
+61 2
A/Prof Harriet Gee is a Staff Specialist in Radiation Oncology at Westmead Hospital. She is also an Adjunct Research Scientist, Children’s Medical Research Institute. Dr Gee graduated with an MBBS from the University of Melbourne, receiving the AMA Prize for the student with the highest overall mark. After basic medical training at Royal Melbourne Hospital, Dr Gee undertook a DPhil (PhD-equivalent) with Professor Adrian Harris at the University of Oxford as a Rhodes Scholar. Her research has been published in leading journals including Nature, Cancer, and Clinical Cancer Research, and focuses on mechanisms of cell death after SABR/SBRT, biomarkers of radiation resistance, and synergy between radiation and immunotherapy.
radiotherapy, SABR, SBRT, radiation resistance, cell death, hypoxia, biomarkers, immunotherapy, microRNAs
Sydney University Extended Stream MD Students, Medical Students (Oncology Block); Medical Students (Respiratory block); co-supervision of Higher Degree students including PhD students
Mechanisms of cell death after ablative dose radiotherapy and implications for combination with immunotherapy; novel radiotherapy-systemic therapy approaches
Fellow, Royal Australian and New Zealand College of Radiologists
Cancer
(University of Oxford) Use of microRNAs and their target genes as markers of hypoxia and radiation resistance | |
(Cleveland Clinic, Cleveland, Ohio) Pragmatic comparison and validation of biomarkers of radiosensitivity | |
(Indiana University) Use of small non-coding RNAs and related genes as markers of hypoxia and radiation resistance |
Publications
Expand all
Journals
- Lau, B., Shirato, H., Taguchi, H., Gensheimer, M., Gee, H., Chin, A., Diehn, M., Loo, B., Moiseenko, V., Vitzthum, L., et al (2024). Chest wall pain after single-fraction thoracic stereotactic ablative Radiotherapy: Dosimetric analysis from the iSABR trial. Radiotherapy and Oncology, 196, 110317. [More Information]
- Brown, L., Ahn, J., Gao, B., Gee, H., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I. (2024). Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy. Cancers, 16(11). [More Information]
- Gensheimer, M., Neal, J., Das, M., Chang, D., Kidd, E., Hancock, S., Shultz, D., Horst, K., Le, Q., Wong, S., Gee, H., et al (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology, 9(11), 1525-1534. [More Information]
show 31 more
Expand all
2024
- Lau, B., Shirato, H., Taguchi, H., Gensheimer, M., Gee, H., Chin, A., Diehn, M., Loo, B., Moiseenko, V., Vitzthum, L., et al (2024). Chest wall pain after single-fraction thoracic stereotactic ablative Radiotherapy: Dosimetric analysis from the iSABR trial. Radiotherapy and Oncology, 196, 110317. [More Information]
- Brown, L., Ahn, J., Gao, B., Gee, H., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I. (2024). Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy. Cancers, 16(11). [More Information]
2023
- Gensheimer, M., Neal, J., Das, M., Chang, D., Kidd, E., Hancock, S., Shultz, D., Horst, K., Le, Q., Wong, S., Gee, H., et al (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology, 9(11), 1525-1534. [More Information]
- Ahn, J., Last, A., Dwyer, P., Ong, A., Aherne, N., Azzi, M., Hau, E., Yeghiaian Alvandi, R., Hegi, F., Browne, L., Gee, H., et al (2023). SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life. International Journal of Radiation Oncology Biology Physics, 117(5), 1213-1221. [More Information]
- Boys, E., Gao, B., Hui, R., Esteves Domingues Pires da Silva, I., Hau, E., Gee, H., Nagrial, A. (2023). Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study. Thoracic Cancer, 14(6), 563-572. [More Information]
2022
- Lee, K., Le, T., Hau, E., Hanna, G., Gee, H., Vinod, S., Dammak, S., Palma, D., Ong, A., Yeghiaian-Alvandi, R., et al (2022). A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 113(1), 40-59. [More Information]
- Merie, R., Gee, H., Hau, E., Vinod, S. (2022). An Overview of the Role of Radiotherapy in the Treatment of Small Cell Lung Cancer – A Mainstay of Treatment or a Modality in Decline? Clinical Oncology, 34(11), 741-752. [More Information]
- Czajkowski, D., Szmyd, R., Gee, H. (2022). Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 66(4), 546-559. [More Information]
show 1 more
2021
- Gensheimer, M., Gee, H., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P., et al (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). International Journal of Radiation Oncology Biology Physics, 111(3), S89-S90. [More Information]
- Di Re, A., Sun, Y., Sundaresan, P., Hau, E., Toh, J., Gee, H., Or, M., Haworth, A. (2021). MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review. Expert Review of Anticancer Therapy, 21(4), 425-449. [More Information]
- Khalil, A., Hau, E., Gebski, V., Grau, C., Gee, H., Nyeng, T., West, K., Kramer, S., Farlow, D., Knap, M., et al (2021). Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial. BMC Cancer, 21(1), 940. [More Information]
show 1 more
2020
- Shen, H., Cook, K., Gee, H., Hau, E. (2020). Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas. Journal of Experimental and Clinical Cancer Research, 39(1), 1-14. [More Information]
- Sia, J., Szmyd, R., Hau, E., Gee, H. (2020). Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. Frontiers in Cell and Developmental Biology, 8, 41. [More Information]
- Dhawan, A., Scott, J., Sundaresan, P., Veness, M., Porceddu, S., Hau, E., Harris, A., Buffa, F., Gee, H. (2020). Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports, 10(1), 1-10. [More Information]
2019
- Lamichhane, S., Thachil, T., Gee, H., Milic, N. (2019). Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis. Disease Markers, 2019. [More Information]
- Gee, H., Moses, L., Stuart, K., Nahar, N., Tiver, K., Wang, T., Ward, R., Ahern, V. (2019). Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure. Journal of Medical Imaging and Radiation Oncology, 63(1), 102-115. [More Information]
2018
- Dhawan, A., Scott, J., Sundaresan, P., Veness, M., Porceddu, S., Hau, E., Ahern, V., Harris, A., Buffa, F., Gee, H. (2018). Are Signatures of Radiosensitivity Ready for Routine Clinical Use? a Pragmatic Comparison of Clinical, Pathological and Gene Signature Predictors of Outcome in Oropharynx Head and Neck Cancers. International Journal of Radiation Oncology Biology Physics, 102(3), S137-S138. [More Information]
- Gee, H., Veness, M. (2018). High-Risk Cutaneous Squamous Cell Carcinoma. Current Otorhinolaryngology Reports, 6(2), 120-128. [More Information]
- Pajic, M., Froio, D., Daly, S., Doculara, L., Millar, E., Graham, P., Drury, A., Steinmann, A., de Bock, C., O'Toole, S., Gee, H., et al (2018). miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Research, 78(2), 501-515. [More Information]
show 1 more
2016
- Gee, H., Bignell, F., Odgers, D., Gill, S., Martin, D., Toohey, J., Carroll, S. (2016). In vivo dosimetric impact of breast tissue expanders on post-mastectomy radiotherapy. Journal of Medical Imaging and Radiation Oncology, 60(1), 138-145. [More Information]
- Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
- Zhang, X., Gee, H., Rose, B., Lee, C., Clark, J., Elliott, M., Gamble, J., Cairns, M., Harris, A., Khoury, S., et al (2016). Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer, 16(1), 1-11. [More Information]
2015
- Gee, H., Buffa, F., Harris, A., Toohey, J., Carroll, S., Cooper, C., Beith, J., McNeil, C., Carmalt, H., Mak, C., Kennedy, C., O'Toole, S., et al (2015). MicroRNA-Related DNA repair/ cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. International Journal of Radiation Oncology Biology Physics, 93(5), 1104-1114. [More Information]
2014
- Gee, H., Ivan, C., Calin, G., Ivan, M. (2014). HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants & Redox Signaling, 21(8), 1220-1238. [More Information]
2013
- Kumar, K., Wigfield, S., Gee, H., Devlin, C., Singleton, D., Li, J., Buffa, F., Huffman, M., Sinn, A., Silver, J., et al (2013). Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 91(6), 749-758. [More Information]
2012
- Gee, H., Hruby, G. (2012). Update on the Management of Merkel Cell Carcinoma. Cancer Forum, 36(3), 1-5. [More Information]
2011
- Buffa, F., Camps, C., Winchester, L., Snell, C., Gee, H., Sheldon, H., Taylor, M., Harris, A., Ragoussis, J. (2011). microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Research, 71(17), 5635-5645. [More Information]
- Gee, H., Buffa, F., Camps, C., Ramachandran, A., Leek, R., Taylor, M., Patil, M., Sheldon, H., Betts, G., Homer, J., et al (2011). The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer, 104(7), 1168-1177. [More Information]
2010
- Gee, H., Camps, C., Buffa, F., Patiar, S., Winter, S., Betts, G., Homer, J., Corbridge, R., Cox, G., West, C., et al (2010). hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 116(9), 2148-2158. [More Information]
- Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J., et al (2010). MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PloS One, 5(4), 1-11. [More Information]
2008
- Gee, H., Camps, C., Buffa, F., Colella, S., Sheldon, H., Gleadle, J., Ragoussis, J., Harris, A. (2008). MicroRNA-10b and breast cancer metastasis. Nature, 455(7216), E8-E9. [More Information]
Selected Grants
2020
- Understanding the molecular mechanisms of cell death in radiotherapy, Cesare A, Gee H, Hau E, National Health and Medical Research Council (NHMRC)/Ideas Grant